Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study

Background: Peptide receptor radionuclide therapy (PRRT) is an emerging therapeutic option for the treatment of neuroendocrine tumors (NETs), and the number of publications in this field has been increasing in recent years. The aim of the present study was to present the research status and summarize the key topics through bibliometric analysis of published PRRT literature.

Methods: A literature search for PRRT research from 2000 to 2019 was conducted using the Science Citation Index Expanded of Web of Science Core Collection (limited to SCIE) on August 4, 2020. The VOSviewer, R-bibliometrix, and CiteSpace software were used to conduct the bibliometric analysis.

Results: From 2000 to 2019, a total of 681 publications (523 articles and 158 reviews) were retrieved. Annual publication outputs grew from three to 111 records. Germany had the largest number of publications, making the largest contribution to the field (n = 151, 22.17%). Active cooperation between countries/regions was observed. Kwekkeboom from the Erasmus Medical Center is perhaps a key researcher in the field of PRRT. The European Journal of Nuclear Medicine and Molecular Imaging and Journal of Nuclear Medicine ranked first for productive (n = 84, 12.33%) and co-cited (n = 3,438) journals, respectively. Important topics mainly included matters related to the efficacy of PRRT (e.g., ⁹⁰Y-dotatoc and ¹⁷⁷Lu-dotatate), the long-term adverse effects of PRRT (e.g., hematologic and renal toxicities), standardization of NETs and PRRT in practice, the development of medical imaging techniques, and the individual dose optimization of PRRT.

Conclusion: Using bibliometric analysis, we gained deep insight into the global status and trends of studies investigating PRRT for the first time. The PRRT field is undergoing a period of rapid development, and our study provides a valuable reference for clinical researchers and practitioners.

Introduction

Peptide receptor radionuclide therapy (PRRT) is a molecularly targeted radiation therapy involving the systemic administration of a radiolabeled peptide (e.g., ⁹⁰Y-dotatoc and ¹⁷⁷Lu-dotatate), which is designed to target receptors overexpressed on tumors (e.g., somatostatin receptor subtype 2) with high affinity and specificity (Zaknun et al., 2013). At present, PRRT is mainly used for the treatment of metastatic or inoperable neuroendocrine tumors (NETs). As an emerging therapeutic option for NETs, the efficacy of PRRT with radiolabelled somatostatin analogs, such as ⁹⁰Y-dotatoc and ¹⁷⁷Lu-dotatate, is encouraging (Imhof et al., 2011; Pfeifer et al., 2011; Kam et al., 2012). For example, a multinational phase III randomized clinical trial evaluated the efficacy of PRRT in patients with advanced, progressive, somatostatin receptor–positive midgut NETs. Two hundred and twenty-nine patients were randomized to either high-dose long-acting release octreotide therapy or ¹⁷⁷Lu-dotatate. The study showed that treatment with ¹⁷⁷Lu-dotatate was associated with significant patient benefit, which paved the way for the approval of Lutathera^® (¹⁷⁷Lu-dotatate) in the United States and Europe (Strosberg et al., 2017; Hennrich and Kopka, 2019). Encouraging results have also been reported from other studies that evaluated ¹⁷⁷Lu-dotatate for the treatment of other subtypes of NETs (Sansovini et al., 2013; Brabander et al., 2017). However, the side effects of PRRT also need to be considered, such as hematologic and renal toxicities (Bodei et al., 2008; Sabet et al., 2013; Sonbol et al., 2020). Furthermore, compared with ¹⁷⁷Lu, ⁹⁰Y-labeled peptides are more likely to result in higher levels of overall toxicity. Additionally, studies have also reported treatments that combine ¹⁷⁷Lu and ⁹⁰Y (Kunikowska et al., 2011; Seregni et al., 2014) as well as the application of PRRT in combination with other therapies, such as chemotherapy (Kong et al., 2014; Claringbold and Turner, 2016; Kong et al., 2017).

Bibliometrics, a widely accepted research method based on statistical and visualization techniques, helps to depict the knowledge structures and developmental trends of a specific field (Tran et al., 2019; Ke et al., 2020). Generally speaking, a bibliometric analysis usually includes the following steps: putting forward research questions, searching databases (e.g., Web of Science and Scopus), collecting and analyzing data, drawing maps, reporting results, and submitting the manuscript (Ke et al., 2020). To date, bibliometrics has been carried out in a wide range of research topics (Zhang et al., 2015; Yang et al., 2018; Tran et al., 2019; Ke et al., 2020), such as health care, environmental science, and energy management. For example, Tran et al. employed this method and found that artificial intelligence has been applied to the field of health care for a wide range of purposes (Tran et al., 2019). Several bibliometric tools have been developed and are now being used frequently, which include VOSviewer, CiteSpace, BICOMB, and BibExcel. The application of these tools allows researchers to evaluate the current state of a subject and identify hotspots with ease, especially for beginners and non-professional researchers.

In recent years, a number of papers focusing on PRRT have been published; however, to the best of our knowledge, there have not been any studies that provide an overview of PRRT from the perspective of bibliometrics. Therefore, we performed a bibliometric analysis to gain a comprehensive view of the research trends concerning PRRT from multiple aspects, including number of publications per year, productive countries/regions, important journals, key references, and research foci. Our aim is to provide a reference for clinical researchers and practitioners.

Methods

Data Source

On August 4, 2020, we conducted a literature search using the Web of Science Core Collection (WoSCC), limited to Science Citation Index-Expanded (SCIE), to identify PRRT-related publications (only “article” and “review”) from the past two decades (from 2000 to 2019) with no language restriction. Our search strategy was adapted from a recently published systematic review (Sonbol et al., 2020) as follows: TOPICS = “peptide receptor radionuclide therapy” OR “peptide receptor radionuclide therapies” OR “lu-dotatoc” OR “lutetium-dota” OR “lu-dotatate” OR “y-dotatate” OR “y-dotatoc” OR “tyr3-octreotide.” All retrieved records were downloaded on August 4, 2020, and imported into bibliometric tools for further analysis.

Statistical Analysis

The annual output (number of publications per year), publication languages, and document types of PRRT research were analyzed by the online data analysis function (“Analyze Results”) of the WoSCC. Journal impact factors were obtained from the 2019 Journal Citation Reports (Clarivate analytics, Philadelphia, PA, United States). VOSviewer (1.6.15) was used to identify productive countries/regions (if one publication was completed by more than one country/region, the publication was assigned equally to all participating countries/regions), journals, main co-cited journals (if a journal has changed its name, they will be considered as different journals when counting), and key references. The desired bibliometric maps were created. On the VOSviewer maps, different bubbles represent elements (countries/regions, journals, and references), while the size of the bubbles represents the number of publications or co-occurrence frequency. A line between two bubbles reflects the relationship, and the thickness of the lines reflects the strength of the relationship between the elements (van Eck and Waltman., 2010; Ke et al., 2020). In this research, the VOSviewer parameters were set as follows: the counting method was full counting, and the threshold (T) of the elements was dependent on the corresponding element. The geographical distribution map of countries/regions was created using R-bibliometrix (Aria and Cuccurullo., 2017). CiteSpace (5.6. R5) is an application for visualizing and analyzing trends and patterns in scientific literature, which was used to construct the dual-map overlay for journals and detect references with strong citation burstness to identify key topics (Hou et al., 2018; Ke et al., 2020). The parameters of CiteSpace were set as follows: link retaining factor (LRF = 3), look back years (LBY = 8), e for top N (e = 2), time span (2000–2019), years per slice (1), links (strength: cosine, scope: within slices), selection criteria (Top N: top 50), and minimum duration (MD = 5). The data were managed using Microsoft Office Excel 2019 (Redmond, Washington, United States).

Results

Annual Output

We identified 681 publications associated with PRRT in the WoSCC from 2000 to 2019. Of these 681 publications, 523 (76.80%) were indexed as “article” and 158 (23.20%) as “review.” English was the predominant language for publications on PRRT, constituting 97.06% (661/681) of the total. The most common non-English language was German, which constituted 1.32% (9/681) of the total, followed by French (6, 0.88%), Spanish (3, 0.44%), Hungarian (1, 0.15%), and Polish (1, 0.15%). The annual publication outputs in the PRRT field are shown in Figure 1. The number of publications varied from year to year, with an average of around 34 publications per year represented by an overall upward trend during the investigated period. There were three (0.44%) and two (0.29%) papers published in 2000 and 2001, respectively. The publication number was greater than 20 in 2010, was greater than 60 in 2015, and was the highest in 2019 (n = 111, 16.30%).

FIGURE 1

FIGURE 1. Number of publications per year (2000–2019).

Country/Region Analysis

A total of 55 countries/regions contributed to PRRT research. The top 15 productive countries/regions are shown in Table 1. Germany published the highest number of papers (n = 151), followed by the Netherlands (n = 142), the United States (n = 132), Italy (n = 106), England (n = 57), Switzerland (n = 48), and France (n = 39). The top 15 countries/regions were distributed across four continents, of which 11 were located in Europe (Figure 2A). Countries/regions (15/55, 27.27%) with number of publications ≥15 (T = 15) were used to construct a country/region co-authorship network (Figure 2B). The network map reflects the state of research activities and communication among these countries/regions. In Figure 2B, Germany, the Netherlands, the United States, and Italy had larger sized bubbles representing higher numbers of papers. There were active collaborations between countries/regions; for example, Germany had close cooperation with the Netherlands, Switzerland, Italy, and the United States.

TABLE 1

TABLE 1. The top 15 most productive countries/regions for PRRT research.

FIGURE 2

FIGURE 2. Regional distribution (A) and network map of countries/regions (B, T = 15) related to PRRT research.

Journal Analysis

More than 200 scholarly journals (n = 214) had published papers on PRRT research. There were four journals with more than 20 publications, of which European Journal of Nuclear Medicine and Molecular Imaging (IF2019 = 7.081, Q1) was the most productive journal publishing 84 scientific publications in the field, followed by Journal of Nuclear Medicine (n = 77, IF2019 = 7.887, Q1), Cancer Biotherapy and Radiopharmaceuticals (n = 21, IF2019 = 2.314, Q3), and Nuclear Medicine Communications (n = 21, IF2019 = 1.334, Q4). The top 12 journals with the greatest contribution to PRRT research accounted for 44.35% (302/681) of the total publications included in this study (Table 2). Journals (12/214, 5.61%) with ≥9 publications (T = 9) were used to construct the citation network map. As can be seen from Figure 3A, European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, Cancer Biotherapy and Radiopharmaceuticals, and Nuclear Medicine Communications had larger sized bubbles representing a higher number of publications. European Journal of Nuclear Medicine and Molecular Imaging had active citation relationships with Journal of Nuclear Medicine, Seminars in Nuclear Medicine, and Cancer Biotherapy and Radiopharmaceuticals.

TABLE 2

TABLE 2. The 12 most active journals and co-cited journals that published papers on PRRT research from 2000 to 2019.

FIGURE 3

FIGURE 3. The network map of scholarly journals (A, T = 9) and co-cited scholarly journals (B, T = 241) for PRRT research.

When two journals are cited simultaneously in one or more publications, the two journals have a co-citation relationship (Ke et al., 2020). There were 2,269 co-cited scholarly journals, and three journals had over 1,000 co-citations, of which two were issued by the United States and one by Germany (Table 2). Journal of Nuclear Medicine had the most co-citations (n = 3,438, IF2019 = 7.887, Q1), followed by European Journal of Nuclear Medicine and Molecular Imaging (n = 3,086, IF2019 = 7.081, Q1) and Journal of Clinical Oncology (n = 1769, IF2019 = 32.956, Q1) (Table 2). Journals (15/2,269, 0.66%) with co-citations ≥ 241 (T = 241) were used to construct the co-citation network. As shown in Figure 3B, Journal of Nuclear Medicine and European Journal of Nuclear Medicine and Molecular Imaging had larger bubbles due to higher co-citations, and Journal of Nuclear Medicine had active co-citation relationships with European Journal of Nuclear Medicine and Molecular Imaging and Journal of Clinical Oncology.

A dual-map overlay of journals was displayed using CiteSpace (Figure 4). The citing and cited journal maps are the left and the right cluster, respectively. The lines that start from the left to the right are citation links (Ke et al., 2020). We found that there were two main citation paths (green). The top green path indicates that papers published in Medicine/Medical/Clinical journals usually cited papers published in Molecular/Biology/Genetics journals, while the bottom green path shows that papers published in Medicine/Medical/Clinical journals primarily cited papers published in Health/Nursing/Medicine journals.

FIGURE 4

FIGURE 4. The dual-map overlay of journals related to PRRT research.

Reference Analysis

Co-cited references are references that have been co-cited in a set of publications (Ke et al., 2020; Hou et al., 2018). The top 12 co-cited references are listed in Table 3. Each reference of the top 12 co-cited references was co-cited at least 102 times. Among them, a publication by Kwekkeboom et al. published in Journal of Clinical Oncology had the highest number of co-citations (2008, 254 citations) (Kwekkeboom et al., 2008), followed by article published by Strosberg et al. (2017, 140 citations) in New England Journal of Medicine (Strosberg et al., 2017), Imhof et al. (2011, 134 citations) in Journal of Clinical Oncology (Imhof et al., 2011), and Rinke et al. (2009, 125 citations) in Journal of Clinical Oncology (Rinke et al., 2009). The number of co-citations in the remaining eight references ranged from 102 to 121. References (12/12,747, 0.09%) with co-citations ≥ 102 (T = 102) were used to construct the co-citation map. As shown in Figure 5, “Kwekkeboom DJ, 2008, Journal of Clinical Oncology (Kwekkeboom et al., 2008)” had the largest size and had active co-cited relationships with “Imhof A, 2011, Journal of Clinical Oncology (Imhof et al., 2011)” and “Bodei L, 2011, European Journal of Nuclear Medicine and Molecular Imaging (Bodei et al., 2011).”

TABLE 3

TABLE 3. The top 12 co-cited references in PRRT research.

FIGURE 5

FIGURE 5. Co-citation map of references (T = 102) from publications on PRRT research.

Burstness Analysis

Burstness detection allows the identification of publications that receive particular attention from related scientific communities during a certain period of time (Ke et al., 2020; Hou et al., 2018). In CiteSpace, the minimum duration of burstness was set to five years in the present research, and 72 references with strong citation burstness were detected (Figure 6). In Figure 6, the length of the line represents the period from 2000 to 2019, in which the red line indicates the time interval of citation burstness. Among the 72 references, citation burstness of 20 references ended in 2015 or later. The strongest burstness (strength = 34.5112) among the 20 references was the article entitled “Treatment with the radiolabelled somatostatin analog [¹⁷⁷Lu-DOTA⁰,Tyr³] octreotate: toxicity, efficacy, and survival” published in Journal of Clinical Oncology by Kwekkeboom et al. with citation burstness lasting from 2010 to 2016 (Kwekkeboom et al., 2008), followed by “Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors” published by Bodei et al. with citation burstness lasting for seven years (2010–2016, strength = 16.5016) (Bodei et al., 2008). Special attention should be paid to three references that had citation burstness ending in 2019: “The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors” published by Zaknun et al. had the strongest citation burstness (strength = 12.9558) (Zaknun et al., 2013), followed by papers published by Sabet et al. (strength = 8.3227) in Journal of Nuclear Medicine (Sabet et al., 2013) and Pfeifer et al. (strength = 7.0531) in Neuroendocrinology (Pfeifer et al., 2011). The citation burstness of these three papers lasted from 2014 to 2019.

FIGURE 6

FIGURE 6. The references with strong citation burstness (MD = 5) of publications related to PRRT research published from 2000 to 2019.

Discussion

Basic Information

Based on the literature from 2000 to 2019 relating to PRRT research from the SCIE of the WoSCC, we performed a bibliometric analysis to gain a comprehensive view of the research trends concerning PRRT during the past two decades and to provide references for researchers in this field. The number of scientific publications reflects the speed of development of a specific research area (Ke et al., 2020). Our research found that three papers were published in 2000 and only two in 2001, which may be related to the fact that the field was still in its infancy. Indeed, the clinical study with ⁹⁰Y-dotatoc was started in Basel in June 1996, and the first clinical studies with ¹⁷⁷Lu-dotadate started in 2000 in Rotterdam, the Netherlands (Levine and Krenning, 2017). The number of annual publications showed significant increases in recent years, especially from 2015, when more than 60 papers were published. Overall, the annual output related to PRRT research followed an upward trend during the investigated period, which suggested that PRRT research has received increasing attention in recent years. Germany, the Netherlands, and the United States were the top three productive countries, two of which are located in Europe and one in North America, demonstrating that these three countries are particularly influential in the field of PRRT research. Among the top 15 countries, there was only one Asian country (India), which indicated that the research capacity of Asian countries/regions in this field is relatively weak. As for journals, European Journal of Nuclear Medicine and Molecular Imaging, the official journal of the European Association of Nuclear Medicine, was the influential journal in the field, which ranked the first in the productive journals and second in the co-cited journals. In addition to European Journal of Nuclear Medicine and Molecular Imaging, there were five other journals that were both top productive journals and top co-cited journals: Journal of Nuclear Medicine, Endocrine-related Cancer, Neuroendocrinology, Seminars in Nuclear Medicine, and Cancer Biotherapy and Radiopharmaceuticals. Journals issued by the United States accounted for the largest proportion of the top 12 active journals (41.67%) and top 12 co-cited journals (58.33%), which indicated that the United States has considerable influence in this field. The dual-map overlay of journals analysis may provide a reference for beginners to conduct research in the field of PRRT. As for scholars in the PRRT research field, in the top 12 co-cited references, Kwekkeboom from Erasmus Medical Center published three papers (Kwekkeboom et al., 2001; Kwekkeboom et al., 2005; Kwekkeboom et al., 2008), indicating that this author made a significant contribution and may be regarded as the representative author in the area of PRRT. Next, we used the co-cited references to find the knowledge base related to PRRT and discussed in the following section.

Knowledge Base

Co-cited references represent how frequently two publications are cited together by other publications and may be regarded as a knowledge base of a specific field or subject (Ke et al., 2020). In our study, the top 12 co-cited references were selected to identify the knowledge base related to PRRT. The study with the highest number of co-citations (n = 254) was published in 2008 by Kwekkeboom et al. (Kwekkeboom et al., 2008), which demonstrated complete or partial tumor remissions in patients with metastasized or inoperable gastroenteropancreatic NETs (GEP-NETs) treated with ¹⁷⁷Lu-dotatate. The preliminary results of this treatment in relatively small patient groups were also reported previously by Kwekkeboom et al. Two of these belonged to the top 12 co-cited references, specifically the sixth and seventh co-cited references (n = 118 and n = 116) published in 2001 (Kwekkeboom et al., 2001) and 2005 (Kwekkeboom et al., 2005), respectively. In 2001, Kwekkeboom et al. found that the ¹⁷⁷Lu-dotatate represents a potentially important improvement because the uptake of radioactivity was comparable to that after [¹¹¹In-DTPA⁰] octreotide in the organs (e.g., kidneys, spleen, and liver) but was three- to fourfold higher in most tumors. In 2005, Kwekkeboom et al. presented the preliminary results of treatment with ¹⁷⁷Lu-dotatate in 131 patients with GEP-NETs showing tumor remission in a high percentage of patients. The second co-cited publication (n = 140) was published in the New England Journal of Medicine by Strosberg et al. (Strosberg et al., 2017). Approval of Lutathera® (¹⁷⁷Lu-dotatate) in the United States and Europe was primarily based on the positive results of this multinational phase III clinical trial, which compared ¹⁷⁷Lu-dotatate treatment with high doses of long-acting release octreotide. In 2011, Imhof et al. published the third co-cited reference in Journal of Clinical Oncology (n = 134). In this clinical phase II trial, patients with neuroendocrine cancers were treated with repeated cycles of ⁹⁰Y-dotatoc. The results showed morphologic response and longer survival in 34.1 and 79% of the patients, respectively; meanwhile, hematologic and renal toxicity was reported in a small number of patients (Imhof et al., 2011). Journal of Clinical Oncology published the fourth most co-cited study by Rinke et al. (Rinke et al., 2009). Unlike the above co-cited references, which evaluated the efficacy and/or safety of PRRT, this study provided evidence that long-acting release octreotide inhibits tumor growth in patients with metastatic well-differentiated midgut NETs. Waldherr et al. published the fifth most co-cited study in 2002, with 121 co-citations. This study evaluated the tumor response to high-dose targeted irradiation with 7.4 GBq/m² of ⁹⁰Y-dotatoc in patients with NETs. Compared with the 6 GBq/m² dose used in a previous study, the 7.4 GBq/m² dose of ⁹⁰Y-dotatoc was well tolerated as a treatment for NETs (Waldherr et al., 2002). The eighth co-cited reference was published by Reubi et al. in 2000. Using cell lines transfected with somatostatin receptor subtypes 1 to 5, Reubi and colleagues evaluated the in vitro binding characteristics of radiolabeled (indium, yttrium, and gallium) and unlabeled somatostatin analogs. One of the results demonstrated in vitro that the somatostatin analog [DOTA⁰,Tyr³] octreotate had an approximately nine fold higher affinity for somatostatin receptor subtype 2 than [DOTA⁰,Tyr³] octreotide. The authors believed that these observations might represent basic principles relevant to the development of other peptide radioligands (Reubi et al., 2000). Yao et al. published the ninth co-cited reference in 2008 (Yao et al., 2008), which examined the epidemiology of NETs and prognostic factors for NETs. The authors observed an increasing trend for incidence of NETs, and histologic grade, primary tumor site, disease stage, etc., were prognostic factors of outcome. Additionally, the authors mentioned some new therapeutic approaches for NETs at the end of the paper, such as PRRT and targeted agents. Similar to the long-acting release octreotide reported in the fourth most co-cited reference (Rinke et al., 2009), two other therapies considered for the treatment of NETs were evaluated in the tenth and eleventh most co-cited articles (Raymond et al., 2011; Yao et al., 2011). They were frequently cited in literature on PRRT treatment of NETs. New England Journal of Medicine published the tenth most commonly co-cited study by Raymond et al. in 2011, an international phase III study of sunitinib vs. placebo in patients with progressive well-differentiated endocrine pancreatic tumor. The results showed that sunitinib significantly reduced the risk of disease progression and led to a prolongation of progression-free survival by 5.6 months (11.1 vs. 5.5 months) compared to placebo (Raymond et al., 2011). The eleventh most commonly co-cited article was published by Yao et al. in New England Journal of Medicine in 2011. This large international placebo-controlled trial evaluated the efficacy of everolimus in 410 patients with progressive pancreatic NET. The risk of disease progression was significantly reduced due to the striking superiority of everolimus, which was demonstrated by a progression-free survival of 11 vs. 4.6 months compared to placebo (Yao et al., 2011). The article published in European Journal of Nuclear Medicine and Molecular Imaging in 2011 received the last co-citations of the top 12, which observed that ¹⁷⁷Lu-dotatate was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). However, considering the bone marrow function of patients and the presence of risk factors for kidney toxicity, it seemed safer to divide cumulative activities into lower activity cycles (Bodei et al., 2011). Based on the top 12 co-cited references, we found that the knowledge base of PRRT research mainly involved the following aspects: efficacy of PRRT (e.g., ⁹⁰Y-dotatoc and ¹⁷⁷Lu-dotatate), adverse effects (e.g., hematologic and renal toxicities) of PRRT, epidemiologic characteristics, and other therapies (e.g., somatostatin analogs and targeted agents) for NETs (e.g., GEP-NETs).

Emerging Topics

Papers with high citation burstness can, to a certain extent, reflect the emerging trends or topics within a field (Hou et al., 2018; Ke et al., 2020). The top 72 references with strong strength citation burstness were identified using CiteSpace; the citation burstness of 20 of them ended in 2015 or later, reflecting the most recent topics in PRRT research; these were selected for further discussion. In regard to the end times for citation burstness, three of these 20 references ended in 2015, six in 2016, eight in 2017, and three in 2019. Based on the research content, six of these 20 references evaluated the efficacy and/or safety of PRRT with a single radioisotope (¹⁷⁷Lu or ⁹⁰Y) or a combination of radioisotopes (¹⁷⁷Lu and ⁹⁰Y) (Kwekkeboom et al., 2008; Bushnell et al., 2010; van Essen et al., 2010; Imhof et al., 2011; Pfeifer et al., 2011; Villard et al., 2012). Among them, the strongest burstness was due to an article published by Kwekkeboom et al. in 2008 (strength = 34.5112), which had a citation burstness that lasted for six years (2011–2016) (Kwekkeboom et al., 2008). The publication with the second highest citation burstness was published in Journal of Clinical Oncology by Imhof et al. in 2011. It had a burstness strength of 9.7435, and the burstness lasted for 5 years (2013–2017) (Imhof et al., 2011). Simply put, these two studies showed encouraging outcomes in patients with NETs treated with ¹⁷⁷Lu-dotatate or ⁹⁰Y-dotatoc. The article with the third highest citation burstness (strength = 8.2677) published by Villard et al. in 2012 evaluated the efficacy of PRRT with ⁹⁰Y-dotatoc vs. ⁹⁰Y-dotatoc plus ¹⁷⁷Lu-dotatoc in patients with NETs, and results showed that the combination of radioisotopes was associated with improved overall survival compared with a single radioisotope (Villard et al., 2012). The fourth highest citation burstness (strength = 7.2011) was a study conducted by Bushnell et al. in 2010, and its burstness lasted for seven years (2011–2017). The results revealed that ⁹⁰Y-dotatoc treatment improved symptoms associated with malignant carcinoids in patients with no treatment alternatives (Bushnell et al., 2010). Neuroendocrinology published the fifth highest citation burstness study of the six references by Pfeifer et al. in 2011. This retrospective study evaluated the treatment responses and adverse effects of PRRT with ¹⁷⁷Lu-dotatate and ⁹⁰Y-dotatoc in patients with NETs, and the authors concluded that the implementation of PRRT provides a valuable new therapeutic option in the treatment of advanced NETs (Pfeifer et al., 2011). Finally, the publication with the sixth highest citation burstness was published by van Essen et al. in 2010, with a burstness strength of 5.9227 that lasted from 2011 until 2017. This study showed that salvage therapy with ¹⁷⁷Lu in patients with bronchial and GEP-NETs is effective and safe (van Essen et al., 2010). Five of these 20 references provided guidelines and criteria; among them, the paper with the strongest burstness was a guideline published by Zaknun et al. in 2013 (strength = 12.9558), for which the citation burstness lasted for six years (2014–2019) (Zaknun et al., 2013). The guidance was formulated through a joint international effort under the auspices of the International Atomic Energy Agency, in cooperation with the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging. It covered the rationale, indications, and contraindications for PRRT; assessment of treatment response; and patient follow-up, and was aimed at guiding nuclear medicine specialists in selecting likely candidates for receiving PRRT and delivering the treatment in a safe and effective manner. The theme of one guideline (Kwekkeboom et al., 2009) issued by European Neuroendocrine Tumor Society in 2009 was similar to the above-mentioned guideline. Moreover, another guideline issued by this society in 2012 was for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of the foregut, midgut, hindgut, and unknown primary (Pavel et al., 2012), where PRRT was discussed as one of the treatment approaches. The remaining two papers provided evaluation criteria and focused on tumor-node-metastasis staging of midgut and hindgut (neuro) endocrine tumors and the response evaluation criteria in solid tumors (Rindi et al., 2007; Eisenhauer et al., 2009). The former aimed to help clinicians find the most suitable treatment for patients at different stages of tumors, such as recommending surgery when complete resection is possible and medical treatment (e.g., somatostatin analogs, interferon, chemotherapy, PRRT, and targeted agents) when tumors are unresectable. The latter offered recommendations on the assessment of treatment outcomes. Of the 20 references, two studies focused on the long-term adverse effects of PRRT. One study published by Sabet et al. in 2013 with burstness that lasted six years (2014–2019) investigated the incidence, severity, and reversibility of long-term hematotoxicity in a large cohort of patients undergoing PRRT with ¹⁷⁷Lu-dotatate for metastatic NETs (Sabet et al., 2013). The second study published by Bodei et al. in 2008 investigated the long-term behavior of the main parameters of renal function in a subgroup of patients treated with ⁹⁰Y-dotatoc or ¹⁷⁷Lu-dotatate in the past decade (Bodei et al., 2008). Given that PRRT is a relatively new method, only a small number of long-term follow-up studies focusing on toxicity after PRRT have been published to date, and thus more prospective studies investigating these aspects are needed. Two publications were reviews about GEP-NETs (Modlin et al., 2008; Kwekkeboom et al., 2010). The study by Modlin et al. in 2008 reviewed GEP-NETs from biological and clinical perspectives and systematically introduced the treatment of GET-NETs. They provided recommendations for current scientific and clinical limitations (Modlin et al., 2008). The other review focused on somatostatin receptor-based imaging and therapy of GEP-NETs (Kwekkeboom et al., 2010). Two articles focused on the use of medical imaging techniques in NETs. As patients with NETs are a very heterogeneous group in terms of symptoms, clinical course, and treatment strategy, imaging modalities could be helpful in selecting the appropriate treatment for each patient (Buchmann et al., 2007; Binderup et al., 2010). One study published by Forrer in 2009, of which the citation burstness lasted for six years (2011–2016), reported that the individual calculation of the bone marrow absorbed dose is necessary for individual dose optimization (Forrer et al., 2009). Individualized and accurate treatment is the trend for PRRT because the current dosing paradigm for Lutathera^® may overtreat some patients, where patients may not require the full four cycles of therapy. The study published by Yao et al. (2008) examined the epidemiology of and prognostic factors for NETs, and the study published by Rinke et al. (2009) evaluated the efficacy of long-acting release octreotide in patients with metastatic well-differentiated midgut NETs. In summary, through in-depth discussion of the 20 references with citation burstness ending in 2015 or later, we found that the most prominent topics for PRRT included matters related to the efficacy (e.g., ⁹⁰Y-dotatoc, ¹⁷⁷Lu-dotatate, and ¹⁷⁷Lu-dotatoc), long-term adverse effects (e.g., hematologic and renal toxicities), standardization of NETs and PRRT in practice, development of medical imaging techniques, and individual dose optimization.

Strengths and Limitations

Our study has several strengths. First, the present study provided a deep insight into the global status and trends of research on PRRT using bibliometric analysis for the first time. Second, widely used tools were applied in our study, which assures the reliability of the data. Third, compared with traditional literature reviews, bibliometric analysis is relatively more objective and comprehensive. Nevertheless, this study should also be considered in light of several limitations, which are similar to other bibliometric analyses. First, we only surveyed publications in the WoSCC database; other databases, such as PubMed, Embase, and Cochrane library, were not searched, which may result in some omitted publications. However, it should be noted that the WoSCC is the most frequently used database for bibliometric analysis (Yang et al., 2018; Ke et al., 2020). Second, differences may exist between the bibliometric analysis results and real-world research conditions. The results of our study came from published research but some important information may not have been published in the form of scientific publications. Third, some recently published important papers might not have gained enough attention from researchers and thus may not be discussed in detail in our study. For example, the review (Nicolas et al., 2019) recommended by a reviewer, which is a review published in 2019, summarized the recent developments (e.g., ²¹³Bi and ²²⁵Ac) in PRRT. Therefore, there is still a need to observe the latest published achievements. Finally, all information was extracted using tools, so there are some issues that we encountered in our study that need attention (e.g., journals changing their names affected our results to some extent). Despite these limitations, this study provides a solid global view on PRRT research from the last two decades.

Conclusion

We used bibliometric analysis to provide a comprehensive overview of the research status of PRRT worldwide during the past two decades. The PRRT field is undergoing a period of rapid development and attracting increased attention from researchers. Germany ranked first for productivity and closely cooperated with other countries, such as the Netherlands and the United States. Kwekkeboom from Erasmus Medical Center is perhaps a key researcher in the field of PRRT. European Journal of Nuclear Medicine and Molecular Imaging and Journal of Nuclear Medicine ranked first in the productive journals and co-cited journals, respectively. The key research topics identified in our study included the efficacy and safety of PRRT, standardization of NETs and PRRT in practice, the development of medical imaging techniques, and individual dose optimization of PRRT. The topics regarding PRRT deserve continued following up by researchers, and we believe that our study provides a valuable reference for clinical researchers and practitioners.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author Contributions

XZ and CL designed this study. XL and YY performed the search. XS and HW collected data. NY and KY rechecked data. CL performed analysis. XL and XZ wrote the manuscript. All authors read and approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors are all grateful to the editor, and the three reviewers for their valuable comments and suggestions, which improved the quality of the manuscript a lot.

References

Aria, M., and Cuccurullo, C. (2017). Bibliometrix: an R-tool for comprehensive science mapping analysis. J. Inform. 11 (4), 959–975. doi:10.1016/j.joi.2017.08.007

CrossRef Full Text | Google Scholar

Binderup, T., Knigge, U., Loft, A., Federspiel, B., and Kjaer, A. (2010). 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16 (3), 978–985. doi:10.1158/1078-0432.CCR-09-1759

PubMed Abstract | CrossRef Full Text | Google Scholar

Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, G. M., Bartolomei, M., et al. (2008). Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur. J. Nucl. Med. Mol. Imaging 35 (10), 1847–1856. doi:10.1007/s00259-008-0778-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., et al. (2011). Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur. J. Nucl. Med. Mol. Imaging 38 (12), 2125–2135. doi:10.1007/s00259-011-1902-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., et al. (2017). Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617–4624. doi:10.1158/1078-0432.CCR-16-2743

PubMed Abstract | CrossRef Full Text | Google Scholar

Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., et al. (2007). Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 34 (10), 1617–1626. doi:10.1007/s00259-007-0450-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Bushnell, D. L., O’Dorisio, T. M., O’Dorisio, M. S., Menda, Y., Hicks, R. J., Cutsem, E. V., et al. (2010). ^90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J. Clin. Oncol. 28, 1652–1659. doi:10.1200/JCO.2009.22.8585

PubMed Abstract | CrossRef Full Text | Google Scholar

Claringbold, P. G., and Turner, J. H. (2016). Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy. Neuroendocrinology 103 (5), 432–439. doi:10.1159/000434723

PubMed Abstract | CrossRef Full Text | Google Scholar

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2), 228–247. doi:10.1016/j.ejca.2008.10.026

PubMed Abstract | CrossRef Full Text | Google Scholar

Forrer, F., Krenning, E. P., Kooij, P. P., Bernard, B. F., Konijnenberg, M., Bakker, W. H., et al. (2009). Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur. J. Nucl. Med. Mol. Imaging 36 (7), 1138–1146. doi:10.1007/s00259-009-1072-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Hennrich, U., and Kopka, K. (2019). Lutathera®: the first FDA and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals 12 (3), 114. doi:10.3390/ph12030114

CrossRef Full Text | Google Scholar

Hou, J. H., Yang, X. C., and Chen, C. M., (2018). Emerging trends and new developments in information science: a document co-citation analysis (2009–2016). Scientometrics 115 (2), 869–892. doi:10.1007/s11192-018-2695-9

CrossRef Full Text | Google Scholar

Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., et al. (2011). Response, survival, and long-term toxicity after therapy with the radiolabelled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29, 2416–2423. doi:10.1200/JCO.2010.33.7873

PubMed Abstract | CrossRef Full Text | Google Scholar

Kam, B. L., Teunissen, J. J., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., et al. (2012). Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 39 (Suppl. 1), S103–S112. doi:10.1007/s00259-011-2039-y

PubMed Abstract | CrossRef Full Text | Google Scholar

Ke, L., Lu, C., Shen, R., Lu, T., Ma, B., and Hua, Y. (2020). Knowledge mapping of drug-induced liver injury: a scientometric investigation (2010–2019). Front. Pharmacol. 11, 842. doi:10.3389/fphar.2020.00842

PubMed Abstract | CrossRef Full Text | Google Scholar

Kong, G., Callahan, J., Hofman, M. S., Pattison, D. A., Akhurst, T., Michael, M., et al. (2017). High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 44 (3), 476–489. doi:10.1007/s00259-016-3527-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Kong, G., Thompson, M., Collins, M., Herschtal, A., Hofman, M. S., Johnston, V., et al. (2014). Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur. J. Nucl. Med. Mol. Imaging 41, 1831–1844. doi:10.1007/s00259-014-2788-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Kunikowska, J., Królicki, L., Hubalewska-Dydejczyk, A., Mikołajczak, R., Sowa-Staszczak, A., and Pawlak, D. (2011). Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging 38 (10), 1788–1797. doi:10.1007/s00259-011-1833-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., et al. (2001). [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med. 28 (9), 1319–1325. doi:10.1007/s002590100574

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., et al. (2008). Treatment with the radiolabelled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124–2130. doi:10.1200/JCO.2007.15.2553

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. M. M., van Eijck, C. H. J., Valkema, R., et al. (2010). Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 17, R53–R73. doi:10.1677/ERC-09-0078

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudła, B., de Herder, W. W., et al. (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabelled somatostatin analogs. Neuroendocrinology 90 (2), 220–226. doi:10.1159/000225951

PubMed Abstract | CrossRef Full Text | Google Scholar

Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., et al. (2005). Radiolabelled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23 (12), 2754–2762. doi:10.1200/JCO.2005.08.066

PubMed Abstract | CrossRef Full Text | Google Scholar

Levine, R., and Krenning, E. P. (2017). Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel levine. J. Nucl. Med. 58 (Suppl. 2), 3S–9S. doi:10.2967/jnumed.116.186502

PubMed Abstract | CrossRef Full Text | Google Scholar

Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., et al. (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9 (1), 61–72. doi:10.1016/S1470-2045(07)70410-2

PubMed Abstract | CrossRef Full Text | Google Scholar

Nicolas, G. P., Morgenstern, A., Schottelius, M., and Fani, M. (2019). New developments in peptide receptor radionuclide therapy. J. Nucl. Med. 60 (2), 167–171. doi:10.2967/jnumed.118.213496

CrossRef Full Text | Google Scholar

Pavel, M., Baudin, E., Couvelard, A., Krenning, E., berg, K., Steinm, T., et al. (2012). ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95 (2), 157–176. doi:10.1159/000335597

PubMed Abstract | CrossRef Full Text | Google Scholar

Pfeifer, A. K., Gregersen, T., Grønbæk, H., Hansen, C. P., Müller-Brand, J., Bruun, K. H., et al. (2011). Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93 (3), 189–196. doi:10.1159/000324096

PubMed Abstract | CrossRef Full Text | Google Scholar

Raymond, E., Dahan, L., Raoul, J. L., Bang, Y-J., Borbath, I., Lombard-Bohas, C., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364 (6), 501–513. doi:10.1056/NEJMoa1003825

PubMed Abstract | CrossRef Full Text | Google Scholar

Reubi, J. C., Schär, J. C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., et al. (2000). Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27 (3), 273–282. doi:10.1007/s002590050034

PubMed Abstract | CrossRef Full Text | Google Scholar

Rindi, G., Klöppel, G., Couvelard, A., Komminoth, P., Körner, M., Lopes, J. M., et al. (2007). TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows. Arch. 451 (4), 757–762. doi:10.1007/s00428-007-0452-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Rinke, A., Müller, H. H., Schade-Brittinger, C., Klose, K-J., Barth, P., Wied, M., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 27 (28), 4656–4663. doi:10.1200/JCO.2009.22.8510

PubMed Abstract | CrossRef Full Text | Google Scholar

Sabet, A., Ezziddin, K., Pape, U. F., Ahmadzadehfar, H., Mayer, K., Pöppel, T., et al. (2013). Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med. 54 (11), 1857–1861. doi:10.2967/jnumed.112.119347

PubMed Abstract | CrossRef Full Text | Google Scholar

Sansovini, M., Severi, S., Ambrosetti, A., Monti, M., Nanni, O., Sarnelli, A., et al. (2013). Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 97 (4), 347–354. doi:10.1159/000348394

PubMed Abstract | CrossRef Full Text | Google Scholar

Seregni, E., Maccauro, M., Chiesa, C., Mariani, L., Pascali, C., Mazzaferro, V., et al. (2014). Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur. J. Nucl. Med. Mol. Imaging 41 (2), 223–230. doi:10.1007/s00259-013-2578-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Sonbol, M. B., Halfdanarson, T. R., and Hilal, T. (2020). Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA. Oncol. 6 (7), 1086–1092. doi:10.1001/jamaoncol.2020.0078

PubMed Abstract | CrossRef Full Text | Google Scholar

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., et al. (2017). Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135. doi:10.1056/NEJMoa1607427

PubMed Abstract | CrossRef Full Text | Google Scholar

Tran, B. X., Vu, G. T., Ha, G. H., Vuong, Q. H., Ho, M. T., Vuong, T. T., et al. (2019). Global evolution of research in artificial intelligence in health and medicine: a bibliometric study. J. Clin. Med. 8 (3), 360. doi:10.3390/jcm8030360

CrossRef Full Text | Google Scholar

van Eck, N. J., and Waltman, L. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84 (2), 523–538. doi:10.1007/s11192-009-0146-3

PubMed Abstract | CrossRef Full Text | Google Scholar

van Essen, M., Krenning, E. P., Kam, B. L., de Herder, W. W., Feelders, R. A., and Kwekkeboom, D. J. (2010). Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 51 (3), 383–390. doi:10.2967/jnumed.109.068957

PubMed Abstract | CrossRef Full Text | Google Scholar

Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., et al. (2012). Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J. Clin. Oncol. 30 (10), 1100–1106. doi:10.1200/JCO.2011.37.2151

PubMed Abstract | CrossRef Full Text | Google Scholar

Waldherr, C., Pless, M., Maecke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., et al. (2002). Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J. Nucl. Med. 43 (5), 610–616.

PubMed Abstract | Google Scholar

Yang, S., Sui, J., Liu, T., Wu, W. W., Xu, S., Yin, L., et al. (2018). Trends on PM2.5 research, 1997-2016: a bibliometric study. Environ. Sci. Pollut. Res. Int. 25 (13), 12284–12298. doi:10.1007/s11356-018-1723-x

PubMed Abstract | CrossRef Full Text | Google Scholar

Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., et al. (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26 (18), 3063–3072. doi:10.1200/JCO.2007.15.4377

PubMed Abstract | CrossRef Full Text | Google Scholar

Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Cutsem, E. V., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364 (6), 514–523. doi:10.1056/NEJMoa1009290

PubMed Abstract | CrossRef Full Text | Google Scholar

Zaknun, J. J., Bodei, L., Mueller-Brand, J., Baum, R. P., Pavel, M. E., Hörsch, D., et al. (2013). The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 40, 800–816. doi:10.1007/s00259-012-2330-6

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, P., Yan, F. W., and Du, C. Q. (2015). A comprehensive analysis of energy management strategies for hybrid electric vehicles based on bibliometrics. Renew. Sustain. Energy Rev. 48, 88–104. doi:10.1016/j.rser.2015.03.093

CrossRef Full Text | Google Scholar